Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

26/1/2022 8:15:00 AM

Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

Covid-19, Coronavirus

Pfizer and BioNTech launch trial of Omicron -targeted Covid vaccine

NEW YORK — Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier.The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Dr Kathrin Jansen, said in a statement.

Read more: TODAY »

Man 'bullies' MRT passenger into saying 'I'm a coward, I'm a coward'

Is this bullying? Read more at stomp.straitstimes.com Read more >>

Crypto trading is best investment when trading with and expert in trading If you wanna earn from trading send a text to Mrs stephinieweller and start trading earn 100% profits with hood signals and mentorship.

Pfizer and BioNTech launch trial of Omicron-targeted COVID-19 vaccineNEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the

Pfizer-BioNTech begin Omicron vaccine trialPfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron -specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday. When will people ever learn that they will never be able to catch up with the latest virus strain. Its the same mistake they are making again as with Alpha strain. In the end docile civilians are the guinea pigs for these live RCT experiments which only profit Big Pharma pockets.

Pfizer and BioNTech launch trial of Omicron-targeted Covid-19 vaccineOmicron targeted vaccine by Pfizer ScottMorrisonMP GregHuntMP BradHazzard ChrisMinnsMP

Advocacy group urges Pfizer to sell more COVID-19 pills to developing countriesNEW YORK: An influential consumer advocacy group is pressing Pfizer to supply more of its new COVID-19 pill Paxlovid to developing countries this year, concerned that access to the treatment will mirror inequalities in vaccines. Public Citizen sent a letter to Pfizer chief executive Albert Bourla on M

Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J Covid-19 shots

Pfizer and BioNTech launch trial of Omicron-targeted COVID-19 vaccineNEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the

Banking on volunteers in the United States, the companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.LinkedIn NEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.Pfizer's CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.Copy to clipboard https://str.

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier. The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial. They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received their third dose of the Pfizer-BioNTech vaccine three to six months earlier. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Dr Kathrin Jansen, said in a statement. Ugur Sahin, CEO of the German biotech company BioNTech added that the protection of the original vaccine against mild and moderate Covid appeared to wane more rapidly against Omicron. Depending on the amount of clinical trial data required by regulators, it may not be possible to realize a current plan to launch an Omicron-targeting vaccine by the end of March, BioNTech said. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalisation with Omicron, we recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement. Pfizer has said that two doses of the original vaccine may not be sufficient to protect against infection from Omicron, and that protection against hospitalisations and deaths may be waning. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalisation with Omicron, we recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement.

Still, the US Centres for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has provided 90 per cent protection against hospitalisation due to Covid-19. Still, the US Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer-BioNTech vaccine has provided 90 per cent protection against hospitalisation due to COVID-19. A spokesperson for Pfizer said that it did not include people older than 55 because the goal of the study was to examine the immune response of participants dosed, rather than estimate vaccine efficacy. Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent Omicron infection. The European Medicines Agency (EMA) said on Friday that international regulators want data from clinical studies like the one being done by Pfizer and BioNTech before approval of a new vaccine. BioNTech Chief Executive Ugur Sahin told Reuters in November that regulators would not likely require testing of an Omicron-based vaccine on humans because it and Pfizer had already created versions of their established vaccine to target the earlier Alpha and Delta variants, with clinical trials continuing. EMA said these studies should show that the new vaccines elicit more neutralising antibodies in the blood than current vaccines and might also protect against new variants of concern. The first involves people who previously received two doses of the current Pfizer-BioNTech vaccine 90-180 days prior to enrollment, and will receive one or two doses of the Omicron vaccine. BioNTech declined to comment on what type of data it was asked to file with regulators. These studies should show that neutralising antibodies in the blood of participants are superior to those elicited by current vaccines. BioNTech Chief Executive Ugur Sahin told Reuters in November that regulators would likely not require testing of an Omicron-based vaccine on humans because it and Pfizer had already created versions of their vaccine to target the earlier Alpha and Delta variants, with clinical trials continuing.

It said an analysis of antibodies elicited by its Omicron-targeted booster should help answer whether shots will be needed that address more than one variant at a time. It hopes to show the antibodies neutralise a spectrum of variants. The Omicron variant has replaced the Delta variant as the dominant lineage in many parts of the world and Omicron itself is now splitting into different subforms, one of which, BA2, is causing particular concern. The Pfizer-BioNTech vaccine was the first Covid shot to be authorized in the West, in December 2020. Still, some scientists question whether any change is currently needed. "The goal of this vaccine is to protect against serious illness," said Dr Paul Offit, an infectious disease expert at the University of Pennsylvania."To date, these vaccines do that, including protection against Omicron. The coronavirus has killed some 5. It said an analysis of antibodies elicited by its Omicron-targeted booster should help answer whether shots will be needed that address more than one variant at a time.

" REUTERS Related topics .